Dirajlal-Fargo S, et al. - Researchers investigated the influence of zinc supplementation on markers of inflammation and monocyte activation in antiretroviral therapy–treated HIV infection. In this phase I open-labeled randomized double-arm study, randomization of 52 (≥ 18-year-old) individuals living with HIV, on stable antiretroviral therapy, with zinc levels ≤ 75 µg/dL in the last 60 days, was done; 25 participants were randomized to receive zinc gluconate capsules at a dose of 45 mg (low-dose), and 27 participants were randomized to received 90 mg (high-dose) elemental zinc daily for 16 weeks. The low-dose arm exhibited an increase in the median circulating zinc levels to 91 µg/dL and the high-dose arm exhibited the increase to 100 µg/dL. The analysis thereby supports the efficacy of zinc supplementation at increasing circulating zinc levels. Findings further provide novel evidence implying the effect of zinc on a biological signature in people living with HIV and its modulation effect on biomarkers associated with clinical comorbidities.